Nov. 12, 2012 | Vol. 11 No. 222 | Full Issue in PDF Format
View the entire issue.
Drug manufacturers and distributors support efforts to establish a national track and trace system, but doubt that a unit-level pedigree system for drugs is feasible.
The FDA is improving its methods and standards for evaluating some extended-release generics after the withdrawal of Impax and Teva’s 300-mg Wellbutrin XL generic because the product was not therapeutically equivalent to its branded counterpart.
A malaria vaccine funded by GlaxoSmithKline (GSK) and the Bill & Melinda Gates Foundation isn’t as effective in African infants as researchers hoped.
Mylan Pharmaceuticals and Famy Care are free to sell a generic version of Janssen Pharmaceuticals’ norgestimate/ethinyl estradiol after Dec. 15, 2015, or earlier under certain circumstances, under a settlement of a patent dispute between the companies.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.